ClinicalTrials.gg
CompletedNCT03776136Updated Oct 9, 2024Results posted

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)

A Phase 2 interventional study of lenvatinib and pembrolizumab in Advanced Melanoma, sponsored by Merck Sharp & Dohme LLC. Completed at 23 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-09.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
103
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate the safety and efficacy of combination therapy of lenvatinib (E7080/MK-7902) and pembrolizumab following approximately 2 years of pembrolizumab therapy and approximately 2 years or more lenvatinib therapy in adult participants with unresectable or advanced melanoma who have been exposed to anti-programmed cell death ligand 1 (PD-1/L1) agents approved for unresectable or metastatic melanoma. No statistical hypothesis will be tested in this study.

02

Conditions studied

  • Advanced Melanoma

Keywords

  • programmed cell death 1 (PD-1, PD1)
  • programmed cell death ligand 1 (PD-L1, PDL1)
  • programmed cell death ligand 2 (PD-L2, PDL2)
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has or cytologically confirmed melanoma
  • Has unresectable Stage III or Stage IV melanoma per American Joint Committee on Cancer (AJCC) staging system version 8 that is not amenable to local therapy
  • Has the presence of ≥1 by computed tomography (CT) or magnetic resonance imaging (MRI) per 1.1 as confirmed by BICR.
  • Has progressed on treatment with an /L1 monoclonal antibody (mAb) administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies
  • Has submitted pre-trial imaging
  • Has an (ECOG) performance status 0 to 1
  • Has provided a baseline tumor
  • Has resolution of toxic effect(s) of the most recent prior therapy to Grade 1 or less (except alopecia). If participant received major surgery or radiation therapy of >30 Gray (Gy), they must have recovered from the toxicity and/or complications from the Intervention
  • Male participants must agree to use approved during the treatment period and for at least 120 days after the last dose of study intervention and refrain from donating sperm during this period
  • Female participants are not pregnant and not breastfeeding, and are not a woman of (WOCBP) or are a WOCBP who agrees to follow contraceptive guidance during the treatment period and for at least 120 days after the last dose of study intervention
  • Has adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days before the first dose of study treatment
  • Has a known additional that is progressing or requires active treatment
  • Has known active central nervous system (CNS) and/or carcinomatous meningitis
  • Has ocular melanoma
  • Has known to active substances or any of their including previous hypersensitivity reaction to treatment with another monoclonal antibody
  • Has an active disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs)
  • Has an active infection requiring systemic therapy
  • Has known history of (HIV) or HIV 1/2 antibodies
  • Has known history of or is positive for (hepatitis B surface antigen [HBsAg] reactive) or (HCV RNA qualitative] is detected)
  • Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease
  • Has a history of active tuberculosis (Bacillus tuberculosis)
  • Has presence of a gastrointestinal condition including malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib
  • Has had major surgery within 4 weeks prior to first dose of study interventions (adequate wound healing after major surgery must be assessed clinically, independent of time elapsed for eligibility)
  • Has a pre-existing Grade ≥3 gastrointestinal or non-gastrointestinal fistula
  • Has radiographic evidence of major blood vessel invasion/infiltration
  • Has clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study drug
  • Has clinically significant cardiovascular disease within 12 months from first dose of study drug, including Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability
  • Has received prior radiotherapy within 2 weeks of Cycle 1 Day 1 with the exception of palliative radiotherapy to bone lesions, which is allowed if completed 2 weeks prior to Cycle 1 Day 1
  • Has received a within 30 days before the first dose of study treatment
  • Is currently participating in or has participated in a study of an agent or has used an investigational device within 4 weeks prior to the first dose of study treatment
  • Has a history or has current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
  • Has had an allogeneic tissue/solid organ transplant
  • Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
103 participants (actual)

Study arms

  • Experimental
    lenvatinib plus pembrolizumab

    Participants receive lenvatinib 20 mg orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.

    Drug: lenvatinib · Biological: pembrolizumab

Interventions

  • Administered orally once a day during each 21-day cycle.

    Also known as: MK-7902, E7080, LENVIMA™

  • Biologicalpembrolizumab

    Administered as an IV infusion on Day 1 Q3W.

    Also known as: MK-3475, Keytruda®

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants in the analysis population who have a confirmed Complete Response (CR: disappearance of all lesions) or a Partial Response (PR: ≥30% decrease in the sum of target lesion diameters without progression in other lesions) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR). Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ).

    Time frame: Up to approximately 55 months

Secondary outcomes

  1. Progression-free Survival (PFS)

    PFS was defined as the time from first day of study intervention to the first documented progressive disease (PD) per RECIST 1.1 by BICR, or death from any cause, whichever occurred first. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method; participants who did not experience a PFS event were censored at the last disease assessment, or the last assessment before new anticancer treatment if new treatment was initiated.

    Time frame: Up to approximately 55 months

  2. Overall Survival (OS)

    OS was defined as the time from the first day of study intervention to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. OS was calculated using the nonparametric Kaplan-Meier method.

    Time frame: Up to approximately 55 months

  3. Duration of Response (DOR)

    For participants who demonstrated a confirmed Complete Response (CR: disappearance of all lesions) or Partial Response (PR: ≥30% decrease in the sum of target lesion diameters without progression in other lesions) per RECIST 1.1, DOR was defined as the time from first documented CR or PR until progressive disease (PD) or death from any cause, whichever occurs first. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). DOR was calculated using the nonparametric Kaplan-Meier method for censored data.

    Time frame: Up to approximately 55 months

  4. Area Under the Concentration Time Curve of Lenvatinib From Time 0 to Infinity (AUC 0-inf)

    AUC0-inf was defined as the area under the concentration-time curve from time zero extrapolated to infinity. Plasma blood samples collected at specified timepoints, were used to estimate AUC0-inf following Lenvatinib and Pembrolizumab administration. Based on the lenvatinib plasma concentration data obtained on Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1, a protocol specified population PK analysis was performed to characterize the steady state AUC0-inf of lenvatinib when co-administered with pembrolizumab.

    Time frame: Cycle 1 Day 1: 0.5 to 4 hours and 6 to 10 hours postdose; Cycle 1 Day 15: Predose and 2 to 12 hours postdose; Cycle 2 Day 1: Predose, 0.5 to 4 hours, and 6 to 10 hours post-dose (each cycle =21 days)

  5. Number of Participants Who Experience At Least One Adverse Event (AE)

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE is presented.

    Time frame: Up to approximately 55 months

  6. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study treatment due to an AE is presented.

    Time frame: Up to approximately 48 months

07

Results

Posted Oct 9, 2024

Participant flow

Participant flow — Overall Study
MilestoneLenvatinib + Pembrolizumab
Started103
Treated103
Completed0
Not completed103
Withdrew: Death85
Withdrew: Withdrawal by subject3
Withdrew: Sponsor decision15

Outcome measures

PrimaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants in the analysis population who have a confirmed Complete Response (CR: disappearance of all lesions) or a Partial Response (PR: ≥30% decrease in the sum of target lesion diameters without progression in other lesions) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR). Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ).

Time frame:
Up to approximately 55 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR)
Percentage of ParticipantsLenvatinib + Pembrolizumab
Objective Response Rate (ORR)21.4 (13.9 to 30.5)
SecondaryProgression-free Survival (PFS)

PFS was defined as the time from first day of study intervention to the first documented progressive disease (PD) per RECIST 1.1 by BICR, or death from any cause, whichever occurred first. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method; participants who did not experience a PFS event were censored at the last disease assessment, or the last assessment before new anticancer treatment if new treatment was initiated.

Time frame:
Up to approximately 55 months
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsLenvatinib + Pembrolizumab
Progression-free Survival (PFS)4.2 (3.5 to 6.3)
SecondaryOverall Survival (OS)

OS was defined as the time from the first day of study intervention to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. OS was calculated using the nonparametric Kaplan-Meier method.

Time frame:
Up to approximately 55 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsLenvatinib + Pembrolizumab
Overall Survival (OS)14.0 (10.8 to 18.3)
SecondaryDuration of Response (DOR)

For participants who demonstrated a confirmed Complete Response (CR: disappearance of all lesions) or Partial Response (PR: ≥30% decrease in the sum of target lesion diameters without progression in other lesions) per RECIST 1.1, DOR was defined as the time from first documented CR or PR until progressive disease (PD) or death from any cause, whichever occurs first. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). DOR was calculated using the nonparametric Kaplan-Meier method for censored data.

Time frame:
Up to approximately 55 months
Reported as:
Median · Months
Duration of Response (DOR)
MonthsLenvatinib + Pembrolizumab
Duration of Response (DOR)8.5 (3.2 to 40.8)
SecondaryArea Under the Concentration Time Curve of Lenvatinib From Time 0 to Infinity (AUC 0-inf)

AUC0-inf was defined as the area under the concentration-time curve from time zero extrapolated to infinity. Plasma blood samples collected at specified timepoints, were used to estimate AUC0-inf following Lenvatinib and Pembrolizumab administration. Based on the lenvatinib plasma concentration data obtained on Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1, a protocol specified population PK analysis was performed to characterize the steady state AUC0-inf of lenvatinib when co-administered with pembrolizumab.

Time frame:
Cycle 1 Day 1: 0.5 to 4 hours and 6 to 10 hours postdose; Cycle 1 Day 15: Predose and 2 to 12 hours postdose; Cycle 2 Day 1: Predose, 0.5 to 4 hours, and 6 to 10 hours post-dose (each cycle =21 days)
Reported as:
Geometric mean · ng*hr/mL
Area Under the Concentration Time Curve of Lenvatinib From Time 0 to Infinity (AUC 0-inf)
ng*hr/mLLenvatinib + Pembrolizumab
Area Under the Concentration Time Curve of Lenvatinib From Time 0 to Infinity (AUC 0-inf)3005 ± 39.5
SecondaryNumber of Participants Who Experience At Least One Adverse Event (AE)

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE is presented.

Time frame:
Up to approximately 55 months
Reported as:
Count of participants · Participants
Number of Participants Who Experience At Least One Adverse Event (AE)
ParticipantsLenvatinib + Pembrolizumab
Number of Participants Who Experience At Least One Adverse Event (AE)102
SecondaryNumber of Participants Who Discontinue Study Treatment Due to an AE

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study treatment due to an AE is presented.

Time frame:
Up to approximately 48 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinue Study Treatment Due to an AE
ParticipantsLenvatinib + Pembrolizumab
Number of Participants Who Discontinue Study Treatment Due to an AE15

Adverse events

Collected over Up to approximately 55 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenvatinib + Pembrolizumab86/103 (83.5%)48/103 (46.6%)101/103 (98.1%)
Most frequent serious events
Showing 10 of 64
Most frequent serious events
EventLenvatinib + Pembrolizumab
DiarrhoeaGastrointestinal disorders5/103
SepsisInfections and infestations4/103
HyponatraemiaMetabolism and nutrition disorders3/103
Abdominal painGastrointestinal disorders2/103
NauseaGastrointestinal disorders2/103
General physical health deteriorationGeneral disorders2/103
PyrexiaGeneral disorders2/103
Cholecystitis acuteHepatobiliary disorders2/103
InfectionInfections and infestations2/103
SyncopeNervous system disorders2/103
Most frequent other events
Showing 10 of 57
Most frequent other events
EventLenvatinib + Pembrolizumab
HypertensionVascular disorders58/103
DiarrhoeaGastrointestinal disorders50/103
NauseaGastrointestinal disorders46/103
Decreased appetiteMetabolism and nutrition disorders42/103
HypothyroidismEndocrine disorders37/103
FatigueGeneral disorders36/103
ConstipationGastrointestinal disorders32/103
AstheniaGeneral disorders31/103
HeadacheNervous system disorders29/103
VomitingGastrointestinal disorders28/103

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Lenvatinib + Pembrolizumab
Mean60.7 ± 13.4
Sex: Female, Male
Sex: Female, Male(Participants)Lenvatinib + Pembrolizumab
Female48
Male55
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lenvatinib + Pembrolizumab
Hispanic or Latino1
Not Hispanic or Latino100
Unknown or Not Reported2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lenvatinib + Pembrolizumab
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American1
White98
More than one race1
Unknown or Not Reported0
08

Study locations

23 sites
  • Ironwood Cancer & Research Centers ( Site 0312)
    Chandler, Arizona 85224, United States
  • John Wayne Cancer Institute ( Site 0301)
    Santa Monica, California 90404, United States
  • Advocate Medical Group-Park Ridge ( Site 0313)
    Park Ridge, Illinois 60068, United States
  • Southeast Nebraska Cancer Center ( Site 0316)
    Lincoln, Nebraska 68510, United States
  • Texas Oncology-Baylor Charles A. Sammons Cancer Center ( Site 0317)
    Dallas, Texas 75246, United States
  • Inova Schar Cancer Institute ( Site 0314)
    Fairfax, Virginia 22031-4867, United States
  • Melanoma Institute Australia ( Site 0152)
    Wollstonecraft, New South Wales 2065, Australia
  • Princess Alexandra Hospital ( Site 0154)
    Woolloongabba, Queensland 4102, Australia
  • Box Hill Hospital ( Site 0157)
    Box Hill, Victoria 3128, Australia
  • Fiona Stanley Hospital ( Site 0156)
    Perth, Western Australia 6150, Australia
  • Lismore Base Hospital ( Site 0153)
    Lismore, 2480, Australia
  • Sunnybrook Research Institute ( Site 0654)
    Toronto, Ontario M4N 3M5, Canada
  • Princess Margaret Cancer Centre ( Site 0655)
    Toronto, Ontario M5G 2M9, Canada
  • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0652)
    Montreal, Quebec H2X 3E4, Canada
  • McGill University Health Centre ( Site 0651)
    Montreal, Quebec H4A 3J1, Canada
  • Hospital Clinic i Provincial Barcelona ( Site 0001)
    Barcelona, 08036, Spain
  • Hospital General Universitario Gregorio Maranon ( Site 0003)
    Madrid, 28007, Spain
  • Hospital Universitario Virgen de la Macarena ( Site 0004)
    Sevilla, 41009, Spain
  • Hospital General Universitario de Valencia ( Site 0002)
    Valencia, 46014, Spain
  • Sahlgrenska Universitetssjukhuset ( Site 0052)
    Goteborg, 413 45, Sweden
  • Skanes Universitetssjukhus ( Site 0053)
    Lund, 221 85, Sweden
  • Karolinska Universitetssjukhuset ( Site 0051)
    Solna, 171 64, Sweden
  • Norrlands Universitetssjukhus ( Site 0056)
    Umea, 901 85, Sweden
09

References and documents

Publications

  • Arance A, de la Cruz-Merino L, Petrella TM, Jamal R, Ny L, Carneiro A, Berrocal A, Marquez-Rodas I, Spreafico A, Atkinson V, Costa Svedman F, Mant A, Khattak MA, Mihalcioiu C, Jang S, Cowey CL, Smith AD, Hawk N, Chen K, Diede SJ, Krepler C, Long GV. Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination. J Clin Oncol. 2023 Jan 1;41(1):75-85. doi: 10.1200/JCO.22.00221. Epub 2022 Jul 22. Erratum In: J Clin Oncol. 2023 May 1;41(13):2454. doi: 10.1200/JCO.23.00439. PubMed 35867951 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Oct 2023, 56 months.

Results were first posted in Oct 2024, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2018
First posted
Dec 14, 2018
StartActual
Jan 30, 2019
Primary completionActual
Oct 11, 2023
CompletionActual
Oct 11, 2023
Results first posted
Oct 9, 2024
Last update
Oct 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03776136
Collaborators
Eisai Inc.
Responsible party
Sponsor
First posted
Dec 14, 2018
Start date
Jan 30, 2019
Primary completion
Oct 11, 2023
Completion
Oct 11, 2023
Results posted
Oct 9, 2024
Last update
Oct 9, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenvatinib · Pembrolizumab

Start the discussion